Navigation Links
endpoint Saves Money and Time for Medical Research Teams Through PULSE
Date:2/9/2010

SAN FRANCISCO, Feb. 9 /PRNewswire/ -- endpoint Clinical (www.endpointclinical.com), a leader in Integrated Voice Response (IVR)/Integrated Web Response (IWR) systems, announced today that PULSE, a fully configurable platform that allows users to design and deploy clinical trial Integrated Response Technology (IRT) systems, saves 40 percent on the development time of clinical trials. This time and cost savings stems from PULSE's ability to provide pre-validated programs so developers do not have to spend valuable time re-configuring studies. For some studies, endpoint will deliver a validated study program in just four weeks rather than eight weeks.

endpoint's PULSE engine gives more control to Clinical Program Managers by allowing them to perform mid-study changes on the fly. Because endpoint's platform contains pre-validated programs, clinical trials can move ahead at a more rapid rate due to project managers having access to the configurable design elements available by PULSE rather than relying on custom development for each change.

"PULSE literally puts the power in the hands of the program manager rather than going through the development team which consumes more time," said Jonathan Dole, co-founder and CEO, endpoint. "Shaving weeks off of the development process for the clinical trial process, PULSE is the holy grail for pharmaceutical and medical companies who want to streamline the trials they sponsor."

Keeping the PULSE on the Clinical Trial Industry

Based on a data-driven platform, PULSE is a rules-based engine that quickly and accurately deploys IRT systems with the highest degree of quality and a vast set of features. By utilizing the pre-validated functions in the PULSE engine, clinical studies are deployed much more quickly and at much less cost. The cost savings is then passed on to the sponsor through a simplified "Not-to- Exceed" pricing structure in which only the active number of sites and patents are billed and there are no telecom fees for the length of the study/trial. PULSE simultaneously deploys systems that can be accessed via the phone, web or mobile device.

"The ultimate benefit from endpoint's PULSE system aside from saving both time and money is that it allows sponsors of smaller, Phase 1 studies to deploy a robust IVR/IWR system to manage the study," said David Joseph-Lacagnina, VP business development, endpoint. "Access to a technology platform that offers them total control of the process is a huge selling point. "This is a great thing for the industry and for sponsors who will ultimately benefit from comprehensive studies that save time and money while allowing for much more control."

About endpoint

endpoint is an innovative company dedicated to the development of the leading technology platforms for the life sciences industry. endpoint's founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. For more information, visit endpoint at www.endpointclinical.com.

SOURCE endpoint

RELATED LINKS
http://www.endpointclinical.com

'/>"/>

SOURCE endpoint
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
2. 012 Smile.Communications Receives License to Provide Endpoint Network Services
3. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
4. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
5. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
6. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
10. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
11. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 18, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, was ... American News. The awards program is based entirely on merit and decided upon ...
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/18/2017)... , January 18, 2017 According to a new market ... Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research ... to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
Breaking Biology News(10 mins):